Marvel Medtech has raised a total of $2,250,000 of capital to date, including a $1.5M federal Phase II SBIR grant program award from the National Cancer Institute/National Institutes of Health (NCI/NIH) in December 2014. The Company is presently seeking Series A equity financing of $3M to supplement the Phase II SBIR grant award, and as matching funding required for submitting a Phase IIb NCI/NIH grant funding proposal of up to $3 million following completion of the Phase II project milestones.
The objective over the next 24 months is to transform the proven concept technology into a clinically-usable, minimum viable product version of the Solada-T™ trocar positioning system, acquire FDA IDE approval, and place multiple systems at select European and U.S. sites to begin clinical evaluations.
An additional financing need of up to $8 million ($5 million if Phase IIb grant funding is awarded) is projected to get the company to sustainable growth, achieving positive cash flow results within about 4 years.
Wisconsin Investor Tax Credits:
Marvel Medtech has been certified as a “qualified new business venture”, making Wisconsin investors eligible for up to $1.25 million of State investor tax credits.
There are well-established recent precedents for acquisition of imaging accessory technology companies such as Marvel Medtech by existing medical imaging OEM (e.g. GE Healthcare, Siemens, Philips) or imaging / interventional technology companies (e.g. Hologic, Devicore). Recent comparable acquisitions of companies similar to Marvel Medtech establish that returns for early investors of 25x to 40x their initial investments have been achieved.
Marvel Medtech anticipates becoming a very attractive acquisition target once our initial product is demonstrated as clinically effective and practical, possibly as soon as initial clinical results are reported in year 2 or 3 (i.e. potentially before Series B funding is needed), but more likely as we begin to achieve noteworthy market traction in year 4-6. Depending upon timing and other decisions, Marvel Medtech’s pro forma financial modeling projects an estimated return of 25x for early-stage investors.